Last reviewed · How we verify
NCT07039682: EKSTRIM
Empowering Knowledge, Self-Testing & Resilience Through Innovative Methods for HIV
NA trial testing Digital HIV Education and Self-Screening (EKSTRIM Model) in Human Immunodeficiency Virus (HIV) Infection in 400 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Universitas Sebelas Maret |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 400 |
| Start date | 31 July 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- Digital HIV Education and Self-Screening (EKSTRIM Model)
Conditions studied
- Human Immunodeficiency Virus (HIV) Infection — all drugs for Human Immunodeficiency Virus (HIV) Infection →
- HIV Prevention — all drugs for HIV Prevention →
- Adolescent Health — all drugs for Adolescent Health →
- Digital Education Interventions — all drugs for Digital Education Interventions →
Sponsor
Universitas Sebelas Maret — full company profile →
Who can join
Adults 15 to 17, any sex, with Human Immunodeficiency Virus (HIV) Infection or HIV Prevention. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to learn whether a digital tool can help improve HIV knowledge, self-awareness, and testing among adolescents in Yogyakarta, Indonesia. The tool includes online HIV education, a self-assessment for HIV risk, and access to trained peer educators for support. The study will also explore how comfortable and willing adolescents are to use this kind of digital health service. The main questions the study aims to answer are: * Can this digital tool help adolescents better understand HIV and their personal risk? * Will more adolescents be willing to get tested for HIV after using the tool? * What factors affect whether adolescents accept and use digital HIV services? Researchers will compare two groups of high school students: * One group will use the digital tool for 6 weeks * The other group will receive standard HIV education (not through the tool) Participants will: * Answer surveys before and after the 6-week period * Learn about HIV through videos and interactive content * Use the tool to assess their personal HIV risk * Receive support from trained peer educators (online) The researchers hope this study will lead to new ways of using technology to improve HIV prevention and testing for young people.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07039682
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Human Immunodeficiency Virus (HIV) Infection
Currently open trials in the same condition.
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
- NCT06886971 — Strategies to AchieVe Viral Suppression for Youth With HIV · NA · recruiting
- NCT04375800 — Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-0 · Phase 2 · recruiting
Other Universitas Sebelas Maret trials
Trials by the same sponsor.
- NCT07475065 — The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy · Phase 2, PHASE3 · not yet recruiting
- NCT07380178 — The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis · NA · completed
- NCT06871358 — The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients · NA · completed
- NCT07121569 — Oral DLBS1033 as Adjunctive Therapy in Acute Ischemic Stroke: Impact on Inflammatory Biomarkers and Outcomes · Phase 4 · completed
- NCT07075289 — Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07039682 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitas Sebelas Maret
- Last refreshed: 26 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07039682.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing